The DOI matches its Crossref record; 859 of the 859 references it cites were found in a registry or an index.
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Open accessAbstract
Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained significant clinical attention in oncology due to their central role in cancer pathogenesis. Genetic alterations, including mutations, amplifications, and overexpression of certain RTKs, are critical in creating environments conducive to tumor development. Following their discovery, extensive research has revealed how RTK dysregulation contributes to oncogenesis, with many cancer subtypes showing dependency on aberrant RTK signaling for their proliferation, survival and progression. These findings paved the way for targeted therapies that aim to inhibit crucial biological pathways in cancer. As a result, RTKs have emerged as primary targets in anticancer therapeutic development. Over the past two decades, this has led to the synthesis and clinical validation of numerous small molecule tyrosine kinase inhibitors (TKIs), now effectively utilized in treating various cancer types. In this manuscript we aim to provide a comprehensive understanding of the RTKs in the context of cancer. We explored the various alterations and overexpression of specific receptors across different malignancies, with special attention dedicated to the examination of current RTK inhibitors, highlighting their role as potential targeted therapies. By integrating the latest research findings and clinical evidence, we seek to elucidate the pivotal role of RTKs in cancer biology and the therapeutic efficacy of RTK inhibition with promising treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 801–859 of 859
Li, J. J., Yan, S., Pan, Y., Liu, Z., Liu, Y., Deng, Q., Tan, Q., Woodward, E. R., & Wu, N. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1480294 · Cited by 13
Prognostic Impact of Phosphorylated Discoidin Domain Receptor-1 in Esophageal Cancer
Sugimoto, K., Ito, T., Woo, J., Tully, E., Sato, K., Orita, H., Brock, M. V., & Gabrielson, E. W. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.10.032 · Cited by 13
New Concepts on the Interactions of Discoidin Domain Receptors with Collagen
Fridman, R. A., & Agarwal, G. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118527 · Cited by 13
Kanemura, H., Takeda, M., Shimizu, S., & Nakagawa, K. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13790 · Cited by 13
Kafri, N. A., & Hafizi, S. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101111 · Cited by 13
Zhu, X., Zhou, R., Lu, Y., Zhang, Y., Chen, Q., & Li, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.763035 · Cited by 13
Diving into the dark kinome: lessons learned from LMTK3
Vella, V., Giamas, G., & Ditsiou, A. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00408-3 · Cited by 13
Shi, Y., Zhou, J., Zhao, Y., Zhu, B., Zhang, L., Li, X., Fang, J., Shi, J., Zhuang, Z., Yang, S., et al. (2023) · BMC Medicine · doi:10.1186/s12916-022-02692-8 · Cited by 13
Ren, S., Wang, X., Han, B., Pan, Y., Zhao, J., Cheng, Y., Hu, S., Liu, T., Li, Y., Cheng, Y., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007227 · Cited by 13
Yamaura, T., Muto, S., Mine, H., Takagi, H., Watanabe, M., Ozaki, Y., Inoue, T., Fukuhara, M., Okabe, N., Matsumura, Y., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11524 · Cited by 12
Jeong, S. U., Hwang, H. S., Park, J.-M., Yoon, S. Y., Shin, S., Go, H., Lee, J., Jeong, G., & Cho, Y. M. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2021.1526 · Cited by 12
Volta, F., Monica, S. L., Leonetti, A., Gnetti, L., Bonelli, M. A., Cavazzoni, A., Fumarola, C., Galetti, M., Eltayeb, K., Minari, R., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-01005-0 · Cited by 12
González-Magaldi, M., McCabe, J. M., Cartwright, H. N., Sun, N., & Leahy, D. J. (2020) · Biochemical Journal · doi:10.1042/bcj20200702 · Cited by 11
Functional characterization of NPM1–TYK2 fusion oncogene
Kuravi, S., Baker, R. W., Mushtaq, M. U., Saadi, I., Lin, T. L., Vivian, C. J., Vallurupalli, A., Abhyankar, S., Ganguly, S., Cui, W., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-021-00246-4 · Cited by 11
Overcoming MET-mediated resistance in oncogene-driven NSCLC
Reischmann, N., Schmelas, C., Molina‐Vila, M. Á., Jordana‐Ariza, N., Kuntze, D., García-Román, S., Simard, M. A., Musch, D., Esdar, C., Albers, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107006 · Cited by 11
SLC12A8 mediates TKI resistance in EGFR-mutant lung cancer via PDK1/AKT axis
Huang, F., Cui, J., Wan, J., Yuan, X., Zhu, Y., Wu, X., Zuo, W., & Zhao, T. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05416-4 · Cited by 11
Correction: A Mutation Causes MuSK Reduced Sensitivity to Agrin and Congenital Myasthenia
Ammar, A. B., Soltanzadeh, P., Bauché, S., Richard, P., Goillot, E., Herbst, R., Gaudon, K., Huzé, C., Schaeffer, L., Yamanashi, Y., et al. (2013) · PLoS ONE · doi:10.1371/annotation/3ff2b918-c83c-4c6f-a2e2-4d91294ec92f · Cited by 10
Novel insulin receptor substrate 1 and 2 variants in breast and colorectal cancer
Esposito, D. L., Verginelli, F., Toracchio, S., Mammarella, S., Lellis, L. D., Vanni, C., Russo, A. D., Mariani‐Costantini, R., & Cama, A. (2013) · Oncology Reports · doi:10.3892/or.2013.2626 · Cited by 10
Kong, W.-M., Guo, Y., Ma, J., & Shi, C. (2023) · Translational Cancer Research · doi:10.21037/tcr-22-2060 · Cited by 10
Joshi, S. K., Pittsenbarger, J., Kennedy, V. E., Peretz, C. A. C., Perl, A. E., Smith, C. C., Tyner, J. W., Druker, B. J., & Traer, E. A. (2023) · American Journal of Hematology · doi:10.1002/ajh.27096 · Cited by 10
Zhang, X., Ishibashi, M., Kitatani, K., Shigeta, S., Tokunaga, H., Toyoshima, M., Shimada, M., & Yaegashi, N. (2020) · Cancers · doi:10.3390/cancers12061705 · Cited by 9
Takumi, Y., Arai, S., Suzuki, C., Fukuda, K., Nishiyama, A., Takeuchi, S., Sato, H., Matsumoto, K., Sugio, K., & Yano, S. (2022) · Cancer Medicine · doi:10.1002/cam4.5342 · Cited by 9
Breitenecker, K., Hedrich, V., Pupp, F., Chen, D., Řezníčková, E., Ortmayr, G., Huber, H., Weber, G., Balcar, L., Pinter, M., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1238883 · Cited by 9
A revised nomenclature for the lemur family of protein kinases
Mórotz, G. M., Bradbury, N. A., Caluseriu, O., Hisanaga, S., Miller, C. C. J., Swiatecka‐Urban, A., Lenz, H., Moss, S. J., & Giamas, G. (2024) · Communications Biology · doi:10.1038/s42003-023-05671-8 · Cited by 9
Goto, K., Kawahara, I., Kuniyasu, H., & Takaki, M. (2015) · The Journal of Physiological Sciences · doi:10.1007/s12576-015-0377-4 · Cited by 8
Xie, L., Xu, J. H., Sun, X., Tang, X., Yan, T., Yang, R., & Guo, W. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.11520 · Cited by 8
Wang, L., Chen, S., Zhong, X., Jiao, X., Liu, K., Qin, B., Wu, Y., Ling, Y., Duan, X.-P., & Zang, Y. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001489 · Cited by 8
Gorachinov, F., Mraiche, F., Moustafa, D. A., Hishari, O., Ismail, Y., Joseph, J. M., Crcarevska, M. S., Dodov, M. G., Geškovski, N., & Goračinova, K. (2023) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.14.23 · Cited by 8
Akın, D. F., & Özkan, D. (2023) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2022.09.010 · Cited by 8
Long non-coding RNAs in non-small cell lung cancer: implications for EGFR-TKI resistance
Liu, D., Lü, X., Huang, W., & Zhuang, W. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1222059 · Cited by 8
Dobre, E.-G., Nichita, L., Popp, C. G., Zurac, S., & Neagu, M. T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042308 · Cited by 8
Ryk modulates the niche activity of mesenchymal stromal cells by fine-tuning canonical Wnt signaling
Jeong, S., Lyu, J., Kim, J., & Oh, I. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0477-y · Cited by 7
Lemur tail kinase 1 (LMTK1) regulates the endosomal localization of β-secretase BACE1
Komaki, K., Takano, T., Satō, Y., Asada, A., Ikeda, S., Yamada, K., Wei, R., Huo, A., Fukuchi, A., Saito, T., et al. (2021) · The Journal of Biochemistry · doi:10.1093/jb/mvab094 · Cited by 7
Parate, S., Kumar, V., Hong, J. C., & Lee, K. W. (2022) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2022.118562 · Cited by 7
SPK1/S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib
Chen, Y., Zhang, R., Mi, D., Wang, Q., Huang, T., Dong, X., Zhang, H., Xiao, H., & Shi, S. (2022) · Gastric Cancer · doi:10.1007/s10120-022-01332-7 · Cited by 7
Shaurova, T., Yan, L., Su, Y., Rich, L. J., Vincent–Chong, V. K., Calkins, H., Pokharel, S., Petkovich, M. P., Seshadri, M., Wu, Y., et al. (2023) · 癌症:英文版 · doi:10.1002/cac2.12401 · Cited by 7
Kim, T., Choi, J., Ahn, M. S., Lee, H. W., Kang, S. Y., Choi, Y. W., Koh, Y. W., & Sheen, S. S. (2024) · BMC Cancer · doi:10.1186/s12885-023-11782-6 · Cited by 7
Mokhdomi, T. A., Bukhari, S., Chikan, N. A., Amin, A., Wafai, A. H., Wani, S. H., Chowdri, N. A., & Qadri, R. A. (2016) · European Journal of Human Genetics · doi:10.1038/ejhg.2016.26 · Cited by 6
The role of MerTK in promoting cell migration is enhanced by the oncogenic Ras/IL‐33 signaling axis
Ohta, S., Tago, K., Kuchimaru, T., Funakoshi‐Tago, M., Horie, H., Aoki‐Ohmura, C., Matsugi, J., & Yanagisawa, K. (2021) · FEBS Journal · doi:10.1111/febs.16271 · Cited by 6
Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma
Gu, Y., Meng, J., Ju, Y., You, X., Sun, T., Lü, J., & Guan, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1027696 · Cited by 6
Chicas-Sett, R., Castilla-Martinez, J., Blanquisett, A. H., Zafra, J., & Pastor-Peidro, J. R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1092875 · Cited by 6
Cuenca, D., Ventura-Gallegos, J. L., Almeda‐Valdés, P., Tusié-Luna, M. T., Reza‐Albarrán, A., Laura, V.-A., Ordoñez-Sánchez, M. L., Segura-Kato, Y., Gomez-Perez, F. J., Conte, M. D. P., et al. (2023) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2023.100965 · Cited by 6
Choi, Y., Cho, Y., Park, S.-Y., Kim, S., Shin, M., Choi, Y., Shin, D. H., Han, J., & Lee, Y. (2022) · Cancers · doi:10.3390/cancers14061512 · Cited by 5
Zhou, Q. H., Wang, M., Zhang, H., Hong, Q., Liu, X., Lu, P., Su, W., & Wu, Y.-L. L. C. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.03.014 · Cited by 5
miRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs
Ravegnini, G., Nannini, M., Indio, V., Serrano, C., Gorini, F., Astolfi, A., Vito, A. D., Morroni, F., Pantaleo, M. A., Hrelia, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012248 · Cited by 5
The magnitude of CXCR4 signaling regulates resistance to quizartinib in FLT3/ITD+ cells via RUNX1
Fukuda, S., Matsuda, N., Shoji, T., Onishi, C., Hirade, T., Taketani, T., & Pelus, L. M. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106983 · Cited by 5
Orlando, E., Medo, M., Bensimon, A., Quintin, A., Riedo, R., Roth, S. M., Riether, C., Marti, T. M., Aebersold, D. M., Medová, M., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04634-2 · Cited by 5
Receptor Tyrosine Kinases and Their Ligands
Heldin, C., & Lennartsson, J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.30001-3 · Cited by 4
Beyond growth signaling: apoptotic sensor MERTK activates AKT by a novel mechanism
Zhang, Y., Earp, H. S., & Liu, P. (2019) · Molecular & Cellular Oncology · doi:10.1080/23723556.2019.1611161 · Cited by 4
Lemur Tyrosine Kinases and Prostate Cancer: A Literature Review
Ferrari, E., Naponelli, V., & Bettuzzi, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115453 · Cited by 4
Zhao, B.-X., Zhang, Y., Shen, L., & Li, M. (2022) · Oncology Reports · doi:10.3892/or.2022.8467 · Cited by 4
Marani, A., Gioacchini, H., Paolinelli, M., Offidani, A., & Campanati, A. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2255519 · Cited by 4
Chakraborty, S., Baruah, R., Mishra, N., & Varma, A. K. (2023) · Genomics & Informatics · doi:10.5808/gi.22069 · Cited by 4
Mahendram, S., Subapanditha, M., McFarlane, N., Venugopal, C., & Singh, S. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800781-5.00017-7 · Cited by 2
Orlando, E., Medo, M., Bensimon, A., Quintin, A., Riedo, R., Roth, S. M., Riether, C., Marti, T. M., Aebersold, D. M., Medová, M., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04725-8 · Cited by 2
Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression
Peters, T. L., Chen, N., Tyler, L. C., Le, A. T., Dimou, A., & Doebele, R. C. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15116 · Cited by 2
Structure and Functions of NGF Receptors
Chao, M. V., Huber, J., Berg, M. M., Benedetti, M., Horvath, C. M., & Hempstead, B. L. (1993) · Springer eBooks · doi:10.1007/978-1-4757-9542-4_3 · Cited by 1
Klempner, S. J., Gowen, K. A., Lee, T. K. M., Zhu, V. W., Schrock, A. B., Miller, V. A., Ali, S. M., & Ou, S. I. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.043 · Cited by 1
The Mechanism of Ligand‐Induced Activation of the Tie Family of Receptor Tyrosine Kinases
Madukwe, J. C., & Ferguson, K. M. (2019) · The FASEB Journal · doi:10.1096/fasebj.2019.33.1_supplement.809.10 · Cited by 1
Cited by
Targeting PP2A in cancer: an underrated option
Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03560-y · Cited by 8
Metadata
- Authors
- Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-08-14
- Volume
- 9
- Issue
- 1
- Pages
- 201-201
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4401593620
- Cited by
- 260
- References
- 859
- FWCI
- 68.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.